These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30397907)

  • 1. Sample size estimation for case-crossover studies.
    Dharmarajan S; Lee JY; Izem R
    Stat Med; 2019 Mar; 38(6):956-968. PubMed ID: 30397907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size re-estimation in crossover trials: application to the AIM HY-INFORM study.
    Wych J; Grayling MJ; Mander AP
    Trials; 2019 Dec; 20(1):665. PubMed ID: 31791376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cluster randomised crossover trials with binary data and unbalanced cluster sizes: application to studies of near-universal interventions in intensive care.
    Forbes AB; Akram M; Pilcher D; Cooper J; Bellomo R
    Clin Trials; 2015 Feb; 12(1):34-44. PubMed ID: 25475880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive propensity score procedure improves matching in prospective observational trials.
    Weber D; Uhlmann L; Schönenberger S; Kieser M
    BMC Med Res Methodol; 2019 Jul; 19(1):150. PubMed ID: 31311500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future cases as present controls to adjust for exposure trend bias in case-only studies.
    Wang S; Linkletter C; Maclure M; Dore D; Mor V; Buka S; Wellenius GA
    Epidemiology; 2011 Jul; 22(4):568-74. PubMed ID: 21577117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of short-term exposure to air pollution on hospital admissions of young children for acute lower respiratory infections in Ho Chi Minh City, Vietnam.
    ; Le TG; Ngo L; Mehta S; Do VD; Thach TQ; Vu XD; Nguyen DT; Cohen A
    Res Rep Health Eff Inst; 2012 Jun; (169):5-72; discussion 73-83. PubMed ID: 22849236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the cluster randomised crossover design: a graphical illustraton of the components of variation and a sample size tutorial.
    Arnup SJ; McKenzie JE; Hemming K; Pilcher D; Forbes AB
    Trials; 2017 Aug; 18(1):381. PubMed ID: 28810895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confounding and exposure trends in case-crossover and case-time-control designs.
    Greenland S
    Epidemiology; 1996 May; 7(3):231-9. PubMed ID: 8728434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size under the additive hazards model.
    McDaniel LS; Yu M; Chappell R
    Clin Trials; 2016 Apr; 13(2):188-98. PubMed ID: 26572562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exact calculation of power and sample size in bioequivalence studies using two one-sided tests.
    Shen M; Russek-Cohen E; Slud EV
    Pharm Stat; 2015; 14(2):95-101. PubMed ID: 25477145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size determination for alternate periods of use study designs with binary responses.
    Morel JG; Neerchal NK
    J Biopharm Stat; 2012; 22(2):351-67. PubMed ID: 22251179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size determination for adaptive crossover trial in detecting gene-drug interactions.
    Chen HY; Darbar D
    Stat Methods Med Res; 2023 Sep; 32(9):1680-1693. PubMed ID: 37431594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinded and unblinded sample size reestimation in crossover trials balanced for period.
    Grayling MJ; Mander AP; Wason JMS
    Biom J; 2018 Sep; 60(5):917-933. PubMed ID: 30073679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control for seasonal variation and time trend in case-crossover studies of acute effects of environmental exposures.
    Bateson TF; Schwartz J
    Epidemiology; 1999 Sep; 10(5):539-44. PubMed ID: 10468428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A note on sample size determination for bioequivalence studies with high-order crossover designs.
    Chen KW; Chow SC; Li G
    J Pharmacokinet Biopharm; 1997 Dec; 25(6):753-65. PubMed ID: 9697082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size importantly limits the usefulness of instrumental variable methods, depending on instrument strength and level of confounding.
    Boef AG; Dekkers OM; Vandenbroucke JP; le Cessie S
    J Clin Epidemiol; 2014 Nov; 67(11):1258-64. PubMed ID: 25124167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size determination for testing nonequality under a three-treatment two-period incomplete block crossover trial.
    Lui KJ; Chang KC
    Biom J; 2015 May; 57(3):410-21. PubMed ID: 25757940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The case-case-time-control study design].
    Wang J; Zhuo L; Zhan S
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Dec; 35(12):1396-9. PubMed ID: 25623463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's disease.
    Putt ME; Ravina B
    Control Clin Trials; 2002 Apr; 23(2):111-26. PubMed ID: 11943439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prior event rate ratio adjustment: numerical studies of a statistical method to address unrecognized confounding in observational studies.
    Yu M; Xie D; Wang X; Weiner MG; Tannen RL
    Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2():60-8. PubMed ID: 22552981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.